无细胞DNA筛查提示单体X阳性:疑似母体或胎儿特纳综合征的临床评估与管理
本文针对无细胞DNA筛查提示单体X阳性时如何评估和管理母体或胎儿特纳综合征提供专家建议,指出该筛查假阳性率高、阳性预测值低,阳性结果可能代表胎儿特纳综合征、母体特纳综合征或局限性胎盘嵌合体,并强调现有国际共识指南未专门涵盖此类情况。
要点
- 无细胞DNA筛查单体X的假阳性率高、阳性预测值低,阳性结果需进一步诊断性评估。
- 单体X阳性可能代表胎儿特纳综合征、母体特纳综合征或局限性胎盘嵌合体。
- 诊断性胎儿核型与筛查结果不一致时,需考虑未识别的母体特纳综合征。
核心结论
- 无细胞DNA筛查单体X阳性时需进行母体和/或胎儿评估以确定真阳性,并区分胎儿与母体特纳综合征。
- 现有国际共识临床实践指南未专门涉及无细胞DNA筛查单体X阳性的管理。
研究设计与样本
- 本文为提供背景和专家驱动建议的研究,旨在为无细胞DNA筛查单体X阳性时的母体和/或胎儿评估与管理提供推荐。
主要发现
- 无细胞DNA筛查性染色体异常尤其是单体X与高假阳性率和低阳性预测值相关。
- 单体X阳性可能代表胎儿特纳综合征、母体特纳综合征或局限性胎盘嵌合体。
- 筛查阳性而诊断性胎儿核型不一致时,需考虑未识别的母体特纳综合征。
关键数值与推荐
- 无细胞DNA筛查可在妊娠9至10周时筛查胎儿性染色体异常如单体X。
临床怎么用
- 本文为无细胞DNA筛查单体X阳性时的母体和/或胎儿评估与管理提供专家驱动建议。
- 确定真阳性及诊断特纳综合征适用于胎儿还是母体。
- confirmed特纳综合征的后续管理参照临床实践指南。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Initially provided as an alternative to evaluation of serum analytes and nuchal translucency for the assessment of pregnancies at high risk of trisomy 21, cell-free DNA screening for fetal aneuploidy, also referred to as noninvasive prenatal screening, can now also screen for fetal sex chromosome anomalies such as monosomy X as early as 9 to 10 weeks of gestation. Early identification of Turner syndrome, a sex chromosome anomaly resulting from the complete or partial absence of the second X chromosome, allows medical interventions such as optimizing obstetrical outcomes, hormone replacement therapy, fertility preservation and support, and improved neurocognitive outcomes. However, cell-free DNA screening for sex chromosome anomalies and monosomy X in particular is associated with high false-positive rates and low positive predictive value. A cell-free DNA result positive for monosomy X may represent fetal Turner syndrome, maternal Turner syndrome, or confined placental mosaicism. A positive screen for monosomy X with discordant results of diagnostic fetal karyotype presents unique interpretation and management challenges because of potential implications for previously unrecognized maternal Turner syndrome. The current international consensus clinical practice guidelines for the care of individuals with Turner syndrome throughout the lifespan do not specifically address management of individuals with a cell-free DNA screen positive for monosomy X. This study aimed to provide context and expert-driven recommendations for maternal and/or fetal evaluation and management when cell-free DNA screening is positive for monosomy X. We highlight unique challenges of cell-free DNA screening that is incidentally positive for monosomy X, present recommendations for determining if the result is a true-positive, and discuss when diagnosis of Turner syndrome is applicable to the fetus vs the mother. Whereas we defer the subsequent management of confirmed Turner syndrome to the clinical practice guidelines, we highlight unique considerations for individuals initially identified through cell-free DNA screening.
引用
- Dowlut-McElroy T, Davis S, Howell S, et al. Cell-free DNA screening positive for monosomy X: clinical evaluation and management of suspected maternal or fetal Turner syndrome. Am J Obstet Gynecol. 2022. PMID: 35841934. doi:10.1016/j.ajog.2022.07.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。